» Articles » PMID: 11532348

Expression of IL-6 and IL-6 Receptors by Circulating Clonotypic B Cells in Multiple Myeloma: Potential for Autocrine and Paracrine Networks

Overview
Journal Exp Hematol
Specialty Hematology
Date 2001 Sep 5
PMID 11532348
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the participation of clonotypic MM B cells in the IL-6 network in patients with multiple myeloma.

Methods: CD19(+) B cells from 45 patients with multiple myeloma and from 18 healthy donors were sorted and their expression of IL-6, IL-6 receptor (CD126) characterized by flow cytometry, in situ RT-PCR, and ELISA measurement of IL-6 and soluble IL-6R. Expression of CD31 was detected by flow cytometry.

Results: Interleukin-6 (IL-6) is a pleiotropic cytokine often overexpressed in multiple myeloma (MM). IL-6 induces growth and inhibits apoptosis of MM plasma cells, and upregulates the activity of osteoclasts. MM plasma cells, the most mature component of the MM clone, secrete IL-6 and induce IL-6 production from other cell types. However, the MM clone also includes circulating clonotypic B lymphocytes. Using ELISA and in situ RT-PCR we demonstrate here that, unlike the healthy control B cells, MM B cells express IL-6 mRNA and secrete IL-6 protein. In vitro, MM B cells were the major producers of IL-6 in peripheral blood mononuclear cells. On average, 50% of MM B cells express the IL-6 receptor (IL-6R, CD126), suggestive of autocrine stimulation. They also express CD31, potentially facilitating their paracrine interactions with osteoclast precursors.

Conclusion: Secretion of IL-6 by circulating clonotypic B cells in MM may contribute to the autocrine and paracrine cytokine networks that maintain the malignant clone and are responsible for disruption of normal bone metabolism in this incurable disease.

Citing Articles

High expression of HOXC6 predicts a poor prognosis and induces proliferation and inflammation in multiple myeloma cells.

Li Z, Wang Y, Hou X, Guo L, Li Y, Ma Y Genes Genomics. 2023; 45(7):945-955.

PMID: 37202556 DOI: 10.1007/s13258-023-01397-3.


Response to pneumococcal vaccination in multiple myeloma.

Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M Cancer Med. 2019; 8(8):3822-3830.

PMID: 31145552 PMC: 6639194. DOI: 10.1002/cam4.2253.


Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar S, Buadi F, Dingli D, Dispenzieri A Bone Marrow Transplant. 2017; 53(2):155-161.

PMID: 29131152 DOI: 10.1038/bmt.2017.228.


IκBε is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner.

Alves B, Tsui R, Almaden J, Shokhirev M, Davis-Turak J, Fujimoto J J Immunol. 2014; 192(7):3121-32.

PMID: 24591377 PMC: 3965642. DOI: 10.4049/jimmunol.1302351.


In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

Debes Marun C, Belch A, Pilarski L Am J Hematol. 2012; 87(6):579-87.

PMID: 22495885 PMC: 3433796. DOI: 10.1002/ajh.23194.